Analytical Data
-
基因名
Fibulin-3
- Application
-
别名
EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q12805
-
表达区间
Cys258~Phe493
-
分子量
27kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibulin-3, also known as EFEMP1, is an extracellular matrix protein that plays a crucial role in various biological processes, including cell adhesion, tissue remodeling, and angiogenesis. Its significance has been highlighted in several studies linking it to various pathologies, particularly in the context of ocular diseases, such as age-related macular degeneration (AMD). Research has shown that Fibulin-3 is involved in the regulation of matrix metalloproteinases (MMPs) and may influence the stability and composition of the extracellular matrix, which are critical for maintaining normal tissue architecture. Mutations and aberrant expression of Fibulin-3 have been associated with increased susceptibility to AMD and other degenerative conditions. As a result, the recombinant form of Fibulin-3 has emerged as a vital tool in both basic and translational research. Scientists are exploring its potential as a biomarker for disease diagnosis and progression, as well as a therapeutic target for strategies aimed at modulating its activity to counteract the effects of matrix dysregulation. By producing recombinant Fibulin-3, researchers can investigate its function in various cellular contexts, study its interactions with other matrix components, and identify potential pathways for intervention in fibrotic conditions and degenerative diseases. This research offers promising avenues for the development of new therapeutic strategies, highlighting the importance of Fibulin-3 in both normal physiology and pathological conditions.
